Donald J. Buchsbaum

Model prediction of treatment planning for dose-fractionated radioimmunotherapy.

Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro.

Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.

Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector.

Rationales, evidence, and design considerations for fractionated radioimmunotherapy.

De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent.

Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agent.

Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice.

Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells.

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.

Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.

An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma.

Invited commentary: targeting of 125I-labeled B lymphocyte stimulator.

Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.

Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts.

Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.

Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.

Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs.

Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells.

Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression.

Gene expression imaging with radiolabeled peptides.

Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.

Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer.

Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

Radiotargeted gene therapy.

The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3.

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.

Gene delivery and gene therapy of prostate cancer.

Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma.

TRAIL receptor-targeted therapy.

Pretargeted radioimmunotherapy.

Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

Oncolytic HSV-1 for the treatment of brain tumours.

Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.

High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts.

Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer.

Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.

TRAIL-receptor antibodies as a potential cancer treatment.

Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.

EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.

TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.

Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.

Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.

Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects.

Molecular targeted therapies for pancreatic cancer.

Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene.

Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.

In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.

Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.

Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1.

Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.

Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.

Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.

Monoclonal antibodies in the treatment of pancreatic cancer.

A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.

DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy.

Overcoming TRAIL resistance in ovarian carcinoma.

KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model.

Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.

Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.

Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation.

Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.

Effect of anti-DR5 and chemotherapy on basal-like breast cancer.

Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.

Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer.

Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin.

The use of retinoids in ovarian cancer: a review of the literature.

The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.

Progress in cancer therapy.

A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.

A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.

Chapter seven--Cancer treatment with gene therapy and radiation therapy.

ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.

The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells.

Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.

Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.

Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.

The Wnt/β-catenin pathway in ovarian cancer: a review.

Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.

Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer?

Effect of niclosamide on basal-like breast cancers.

Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

Recurrent read-through fusion transcripts in breast cancer.

Pazopanib combined with radiation: in vivo model of interaction.

Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.